WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Man, 52, reveals how he fell in love with his 98Rishi Sunak tells university bosses to show 'zero tolerance' towards antiJohn Swinney clashes with SNP's former Green allies over 'regressive' decision to make antiDid Prince Harry try to upstage his family by making royalThe Flores agreement has protected migrant children for nearly 3 decades. Changes may be coming.Crochet strikes out 11 to help the White Sox beat the Guardians 6Neymar left off Brazil's squad for Copa America. 17Mother's Day is a sad reminder for the mothers of Mexico's over 100,000 missing peopleOrioles owner takes a turn in the Camden Yards 'Splash Zone'James Simons, mathematician, philanthropist and hedge fund founder, has died
3.4584s , 6501.703125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Grasp news portal